Personalis
Fremont, California, United States · Bioinformatics, Biotechnology, Genetics
Personalis, Inc. (NASDAQ: PSNL) is a company focused on transforming the active management of cancer through personalized testing, guiding care from diagnosis through treatment.
Key facts
- Headquarters
- Fremont, California, United States
- Employees
- Unknown
- Industries
- Bioinformatics, Biotechnology, Genetics
- Status
- Public (PSNL)
- Website
- personalis.com
- Company page
Recent activity at Personalis
- : Personalis, Inc. Secures New Task Order with U.S. Department of Veterans Affairs
- : SEC 8-K (8.01): On August 20, 2026, Personalis, Inc. entered into a new task order under its existing contract with the U.S. Department of Veterans Affairs for the Million Veteran Program. This task order, with a potential value of up to $18.3 million, is effective from September 30, 2026, contingent upon the receipt of samples from the VA MVP and performance of services by Personalis. The additional task order raises the total cumulative value of Personalis' contracts with the VA MVP to approximately $243.3 million, indicating a significant expansion in their business relationship with the VA.
- : Personalis Promotes Dr. Richard Chen to President and CMO
- : SEC 8-K (2.01): On November 7, 2025, Personalis, Inc. announced that its ultrasensitive NeXT Personal® test received Medicare coverage for post-treatment surveillance of cancer recurrence specifically in patients with stage II and III breast cancer. This coverage, determined by the Centers for Medicare & Medicaid Services, is effective retroactively from October 7, 2025, and includes a reimbursement rate of $3,878 for the NeXT Personal Dx Breast MRD Recurrence Monitoring Test and $1,158 for the NeXT Personal Single Plasma Test. This strategic move is significant as it provides coverage for the plasma test for up to six years post-treatment and allows for the breast test to be administered once per cancer diagnosis, thereby potentially enhancing market accessibility for these tests.
- : Personalis, Inc.
Personalis funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2017 | Venture | $12.2M |
Leadership
- Jenevieve Fisher, Regional Director of Sales, Director of Pediatric Initiatives
- Vincent Miles, Director
- Ken Ludlum, Director
- Patrick Balthrop, Director
- Jonathan MacQuitty, Director
- Chris Schaepe, Director
- John West, Executive Officer, Director
- Richard Chen, Chief Medical Officer
- Carol Tillis, Executive Officer
Verified email and direct lines for Personalis’s decision-makers are on Fundz. See plans
Employee benefit plans
Personalis files 6 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Personalis in the news
- Personalis Reports Second Quarter Results and Recent Highlights - Business Wire (Aug 04, 2026)
- Tempus to buy cancer test maker Personalis for $1.5B - MedTech Dive (Jul 20, 2026)
- Tempus buys out cancer genomics partner Personalis in $1.5 billion deal - Fierce Biotech (Jul 20, 2026)
- Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors - Business Wire (May 13, 2026)
- Shareholder Alert: Ademi LLP investigates whether Personalis, Inc. is obtaining a Fair Price for Public Shareholders - PR Newswire (Jul 20, 2026)
- Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain - Business Wire (Jul 14, 2026)
- $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Personalis, Inc. (NASDAQ: PSNL) - PR Newswire (Jul 21, 2026)
- Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring - Business Wire (May 20, 2026)
Companies similar to Personalis
- Akoya Biosciences · Bioinformatics, Biotechnology, Genetics, Health Care, Health Diagnostics
- Breakthrough Genomics · Bioinformatics, Biotechnology, Genetics, Health Care, Health Diagnostics
- Genomic Testing Cooperative · Bioinformatics, Biotechnology, Genetics, Health Care, Health Diagnostics
- Genoox · Bioinformatics, Biotechnology, Genetics, Health Care, Health Diagnostics
- GenePlanet · Bioinformatics, Biotechnology, Genetics, Health Care, Health Diagnostics
About Personalis: questions and answers
What does Personalis do?
Personalis, Inc. (NASDAQ: PSNL) is a company focused on transforming the active management of cancer through personalized testing, guiding care from diagnosis through treatment.
Where is Personalis headquartered?
Personalis is headquartered in Fremont, California, United States.
Has Personalis raised funding?
Yes. Fundz has recorded 1 funding event for Personalis. The most recent, $12.2M, was in Jul 2017.
What is the latest news on Personalis?
On Aug 20, 2026, Personalis, Inc. Secures New Task Order with U.S. Department of Veterans Affairs
Is Personalis a public company?
Yes. Personalis is publicly traded under the ticker PSNL.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy